MARKET

ARMP

ARMP

Armata Pharmaceuticals Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

4.100
-0.030
-0.73%
Closed 16:00 04/16 EDT
OPEN
4.235
PREV CLOSE
4.130
HIGH
4.235
LOW
4.100
VOLUME
9.67K
TURNOVER
--
52 WEEK HIGH
10.48
52 WEEK LOW
2.560
MARKET CAP
102.26M
P/E (TTM)
-2.8965
1D
5D
1M
3M
1Y
5Y
BRIEF-Innoviva Inc - Jules Haimovitz Appointed To Board Of Armata Pharmaceuticals
reuters.com · 04/05 22:22
Aptose Biosciences, Brainstorm Cell Therapeutics leads healthcare gainers; Benitec Biopharma, Second Sight Medical Products among major losers
Gainers: Aptose Biosciences (APTO) +65%, Brainstorm Cell Therapeutics (BCLI) +13%, Prothena (PRTA) +12%, Armata Pharmaceuticals (ARMP) +8%, Inventiva (IVA) +8%.Losers: Benitec Biopharma (BNTC) -24%, Second Sight Medical Products (EYES) -19%, PMV Pharmaceut...
Seekingalpha · 03/24 15:00
DJ Armata Pharmaceuticals Price Target Raised to $7.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 03/22 10:39
DJ Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/22 10:39
Armata Pharmaceuticals (ARMP) Receives a Buy from Ladenburg Thalmann & Co.
SmarterAnalyst · 03/19 10:45
BRIEF-Armata Pharmaceuticals Posts Q4 Revenue $500,000
reuters.com · 03/18 21:30
Armata Pharmaceuticals EPS misses by $0.08, beats on revenue
Armata Pharmaceuticals (ARMP): Q4 GAAP EPS of -$0.36 misses by $0.08.Revenue of $0.5M beats by $0.3M.As of December 31, 2020, Armata held approximately $9.7 million of unrestricted cash and cash
Seekingalpha · 03/18 20:31
Armata Pharmaceuticals 4Q Rev $504,000 >ARMP
Armata Pharmaceuticals 4Q Rev $504,000 >ARMP
Dow Jones · 03/18 20:14
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARMP. Analyze the recent business situations of Armata Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARMP stock price target is 7.75 with a high estimate of 9.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 119.54K
% Owned: 0.48%
Shares Outstanding: 24.94M
TypeInstitutionsShares
Increased
4
43.82K
New
0
0
Decreased
5
147.23K
Sold Out
13
36.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Non-Executive Chairman/Independent Director
Richard Bastiani
President
Brian Varnum
Chief Executive Officer/Director
Todd Patrick
Chief Financial Officer
Steven Martin
Vice President - Operations
Duane Morris
Vice President
Mina Pastagia
Other
Heather Jones
Director
Robin Kramer
Independent Director
Odysseas Kostas
Independent Director
Joseph Patti
Independent Director
Todd Peterson
Independent Director
Sarah Schlesinger
No Data
  • All
  • Financials
  • Insiders
More
About ARMP
Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.

Webull offers kinds of Armata Pharmaceuticals Inc stock information, including AMEX:ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARMP stock methods without spending real money on the virtual paper trading platform.